Scientists identify target receptors for the treatment of glioblastoma

The researchers said they identified a type of receptor called protein-tyrosine Z phosphatase, or PTPRZ, as a drug target for patients with glioblastoma .

Glioblastoma has been classified by the World Health Organization as the highest level of fibroids, a type of brain tumor that is hard to cure with an average survival rate of only 14 months.

The lack of effective treatments for this disease has prompted researchers to look for other better treatments.

Researchers at the Institute of Basic Biology, or NIBB, have identified PTPRZ as an important factor to maintain the properties of stem cells and tumors in glioblastoma cells and by targeting PTPRZ, the Tumor growth can be strongly inhibited on glioblastoma C6 cells in mice.

The study also showed that the allosteric inhibitor of PTPRZ NAZ2329 could prevent stem cell-like properties in glioblastoma cells in culture and tumor growth in glioblastoma C6 cells.

Research published in the Journal of Scientific Reports shows that PTPRZ may be an important target for glioblastoma therapy.